When testing for an interaction between categorical age and treatment, similar results were found without any significant interactions, except for an interaction of borderline significance on net clinical benefit (interaction with categorical age, P = 0.042).
In this trial, there was a highly significant interaction between treatment and age for major bleeding. 18 Both doses of dabigatran compared with warfarin were associated with lower risks of major bleeding in patients aged <75 years, but similar risk (110 mg dose) or higher risk (150 mg dose) of major bleeding in those aged ≥75 years.